RecruitingPhase 2NCT06375005

Efficacy and Safety of Telitacicept in the Treatment of Systemic Sclerosis

Studying Diffuse cutaneous systemic sclerosis

Last synced from ClinicalTrials.gov May 7, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University
Principal Investigator: JING XUE, PhD
Second Affiliated Hospital, School of Medicine, Zhejiang University
Intervention: Telitacicept(drug)
Enrollment: 38 enrolled
Eligibility: 18-70 years · All sexes
Timeline: 2025 – 2027

Study locations (9)

Affiliated Hospital of Yangzhou University, Yangzhou, Jiangsu, China
Huashan Hospital of Fudan University, Shanghai, Shanghai Municipality, China
Hangzhou First People's Hospital, Hangzhou, Zhejiang, China
Sir Run Run Shaw Hospital, Zhejiang University School Of Medicine, Hangzhou, Zhejiang, China
The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
Changxing People's Hospital, Huzhou, Zhejiang, China
The First Hospital of Jiaxing, Jiaxing, Zhejiang, China
Ningbo First Hospital, Ningbo, Zhejiang, China
The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06375005 on ClinicalTrials.gov

Other trials for Diffuse cutaneous systemic sclerosis

Additional recruiting or active studies for the same condition.

See all trials for Diffuse cutaneous systemic sclerosis →

← Back to all trials